**Table S4. Comparison of the predictive value for patients with HBV-ACLF in validation cohorts**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Model | AUC (95% CI) | *Z*-value | *p-*value | AUC (95% CI) | *Z*-value | *p-* value |
| *n* = 94 | |  |  | *n* = 93 |  |  |
| ACTIG | 0.897 (0.818-0.950) | |  | 0.878 (0.794-0.937) | |  |
| MELD | 0.819 (0.726-0.891) | 2.414 | 0.016 | 0.829 (0.737-0.899) | 1.359 | 0.174 |
| MELD-Na | 0.825 (0.733-0.896) | 2.224 | 0.026 | 0.832 (0.740-0.902) | 1.267 | 0.205 |
| iMELD | 0.796 (0.701-0.872) | 2.518 | 0.012 | 0.803 (0.708-0.878) | 1.936 | 0.053 |
| CLIF-C ACLFs | 0.838 (0.747-0.906) | 1.286 | 0.198 | 0.823 (0.730-0.895) | 1.256 | 0.209 |
| COSSH-ACLFs | 0.863 (0.777-0.926) | 1.044 | 0.296 | 0.829 (0.737-0.899) | 1.490 | 0.136 |

CLIF‐C ACLF, Chronic Liver Failure Consortium Acute‐on‐Chronic Liver Failure score; COSSH‐ACLF: Chinese Group on the Study of Severe Hepatitis B; MELD: Model for End‐stage Liver Disease score; MELD-Na: MELD sodium; iMELD: the integrated MELD.